Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in active thyroid eye disease
NCT05795621Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thyroid eye disease (TED) comparing IBI311 with Placebo (2 arms). Primary endpoint: Proptosis responder rate of the study eye at Week 24. Started Feb 2023; status: completed.
02
Drugs
sycume
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05795621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795621.